- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01432561
Study in Healthy Adults to Determine the Effect That Food Has on the Absorption and Delivery of the Drug Cystagon™
September 23, 2013 updated by: Ranjan Dohil, University of California, San Diego
Food-Effect on Bioavailability of Cystagon™ in Normal, Healthy Adults
In order to meet FDA standards of safety and efficacy reporting for most new drugs, food-effect bioavailability (the impact that the presence of food in the digestive tract has on the rate and extent at which a drug is absorbed into the bloodstream and delivered to the site of action) must be collected.
Cystagon™ is an FDA approved drug for the treatment of the rare disease cystinosis that became available in 1994, but there is inadequate knowledge of the food-effect on this drug's bioavailability.
This study aims to investigate how food affects the absorption of Cystagon™ into the bloodstream of normal healthy adults.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
8
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
La Jolla, California, United States, 92093
- University of California, San Diego Center for Clinical Research Services (CCR)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female, smoker (no more than 25 cigarettes daily) or non-smoker, 18 years of age and older, with BMI > 18 and < 30.0.
- Females of childbearing potential who are sexually active must be willing to use two forms of contraceptive methods throughout the study and for 14days after the last study drug administration.
- Minimum weight of 50 kg.
- Good health, defined as not having history of any chronic illness and not requiring any regular medication/therapy.
- Must swallow tablets on a regular basis.
Exclusion Criteria:
- Evidence of Helicobacter pylori infection, presently, or within the last year.
- Subjects with known hypersensitivity to cysteamine.
History, currently or within the past 3 months, of the following conditions:
- Pancreatitis
- Inflammatory bowel disease
- Malabsorption
- Severe liver disease
- Unstable heart disease, e.g., myocardial infarction, heart failure, arrhythmias.
- Unstable diabetes mellitus
- Any bleeding disorder.
- Zollinger-Ellison syndrome
- Malignant disease
- Subjects whom may be pregnant or have health issues that make it unsafe for them participate, or whose concomitant medical problems preclude them from committing to the study schedule.
- Use of an investigational drug within 30 days (or 90 days for biologics) prior to dosing.
- Use of prescription medication within 14 days prior to the first dosing;
- Use over-the-counter products including natural health products (e.g. food supplements and herbal supplements) within 7 days prior to the first dosing.
- Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to dosing.
- Hemoglobin <13.5 g/dL (males) and <12.0 g/dL (females) and hematocrit <41.0% (males) and <36.0% (females) at screening.
- Breast-feeding subject.
- Immunization with a live attenuated vaccine 1 month prior to dosing or planned vaccination during the course of the study.
Presence of fever (body temperature >37.6°C) (e.g. a fever associated with a symptomatic viral or bacterial infection) within 2 weeks prior to dosing.
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cysteamine bitartrate
Cysteamine bitartrate, 500mg once a day, three days.
|
500 mg total, single dose taken orally on visits 2, 3 & 4 which must occur within a 14 day period.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cysteamine Absorption: Area Under the Plasma Concentration Curve (AUC)
Time Frame: 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180 minutes, and 3.5, 4, 4.5, 5, 6 hours post-dose
|
Subjects were randomized to one of two possible treatment sequences using block randomization: Sequence 1 - fasted, high-fat, high-protein or Sequence 2 - high-protein, high-fat, fasted.
Sequence assignment determined the treatment condition corresponding to Period I, II & III visits.
|
0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180 minutes, and 3.5, 4, 4.5, 5, 6 hours post-dose
|
Peak Plasma Cysteamine Concentration (Cmax)
Time Frame: 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180 minutes, and 3.5, 4, 4.5, 5, 6 hours post-dose
|
Subjects were randomized to one of two possible treatment sequences using block randomization: Sequence 1 - fasted, high-fat, high-protein or Sequence 2 - high-protein, high-fat, fasted.
Sequence assignment determined the treatment condition corresponding to Period I, II & III visits.
|
0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180 minutes, and 3.5, 4, 4.5, 5, 6 hours post-dose
|
Time to Peak Plasma Cysteamine Concentration (Tmax)
Time Frame: 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180 minutes, and 3.5, 4, 4.5, 5, 6 hours post-dose
|
Subjects were randomized to one of two possible treatment sequences using block randomization: Sequence 1 - fasted, high-fat, high-protein or Sequence 2 - high-protein, high-fat, fasted.
Sequence assignment determined the treatment condition corresponding to Period I, II & III visits.
|
0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180 minutes, and 3.5, 4, 4.5, 5, 6 hours post-dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Ranjan Dohil, M.D., University of California, San Diego
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Gahl WA, Thoene JG, Schneider JA. Cystinosis. N Engl J Med. 2002 Jul 11;347(2):111-21. doi: 10.1056/NEJMra020552. No abstract available.
- Gahl WA, Reed GF, Thoene JG, Schulman JD, Rizzo WB, Jonas AJ, Denman DW, Schlesselman JJ, Corden BJ, Schneider JA. Cysteamine therapy for children with nephropathic cystinosis. N Engl J Med. 1987 Apr 16;316(16):971-7. doi: 10.1056/NEJM198704163161602.
- Markello TC, Bernardini IM, Gahl WA. Improved renal function in children with cystinosis treated with cysteamine. N Engl J Med. 1993 Apr 22;328(16):1157-62. doi: 10.1056/NEJM199304223281604.
- Smolin LA, Clark KF, Thoene JG, Gahl WA, Schneider JA. A comparison of the effectiveness of cysteamine and phosphocysteamine in elevating plasma cysteamine concentration and decreasing leukocyte free cystine in nephropathic cystinosis. Pediatr Res. 1988 Jun;23(6):616-20. doi: 10.1203/00006450-198806000-00018.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2011
Primary Completion (ACTUAL)
December 1, 2011
Study Completion (ACTUAL)
December 1, 2011
Study Registration Dates
First Submitted
September 9, 2011
First Submitted That Met QC Criteria
September 12, 2011
First Posted (ESTIMATE)
September 13, 2011
Study Record Updates
Last Update Posted (ESTIMATE)
October 9, 2013
Last Update Submitted That Met QC Criteria
September 23, 2013
Last Verified
September 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 111011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystinosis
-
Nacuity Pharmaceuticals, Inc.Recruiting
-
Cystinose StiftungLabor Becker & Kollegen, Munich, Germany; Screening Labor Hannover; Genetikum... and other collaboratorsCompletedSpinal Muscular Atrophy | Cystinosis | Cystinosis, NephropathicGermany
-
Chiesi SA/NVEnrolling by invitationNephropathic CystinosisBelgium
-
Eloxx Pharmaceuticals, Inc.TerminatedGenetic Disease | Cystinosis | Nonsense MutationCanada
-
Stanford UniversityRecruiting
-
Recordati Rare DiseasesCompletedCystinosisBelgium, France, United Kingdom, Germany, Italy
-
University of California, San DiegoEnrolling by invitationCystinosisUnited States
-
Hospices Civils de LyonCompleted
-
National Human Genome Research Institute (NHGRI)Recruiting
-
University of California, San DiegoCalifornia Institute for Regenerative Medicine (CIRM); Cystinosis Research...Active, not recruiting
Clinical Trials on Cysteamine bitartrate
-
National Institute of Diabetes and Digestive and...National Cancer Institute (NCI); National Center for Advancing Translational... and other collaboratorsCompletedNonalcoholic Fatty Liver Disease (NAFLD)United States
-
Horizon Pharma USA, Inc.CompletedCystinosisFrance, United States, United Kingdom, Belgium, Italy, Netherlands
-
Horizon Pharma USA, Inc.CompletedInherited Mitochondrial Disease, Including Leigh SyndromeUnited States
-
Horizon Pharma USA, Inc.CompletedCystinosisFrance, United States, Netherlands
-
Chiesi SA/NVEnrolling by invitationNephropathic CystinosisBelgium
-
Hospices Civils de LyonCompleted
-
Augusta UniversityTerminatedSchizophrenia | SchizoaffectiveUnited States
-
Icahn School of Medicine at Mount SinaiTerminated
-
Horizon Pharma USA, Inc.Terminated